T-cell receptor recognizing HIV-1 Gag, Pol, or Nef peptide presented by major histocompatibility complex class I or II (TCR (HIV-1 Gag/Pol/Nef-specific))

T-cell receptors (TCRs) recognizing HIV-1 Gag, Pol, or Nef peptides presented by major histocompatibility complex (MHC) class I or II molecules are clonotypic cell surface receptors expressed on T lymphocytes that mediate antigen-specific immune responses during HIV infection. TCRs expressed by CD8+ T lymphocytes recognize peptides (usually 8–11 amino acids) from HIV-1 Gag, Pol, or Nef proteins when presented by MHC class I molecules, leading to cytotoxic killing of infected cells[3][4][5][8]. CD4+ T-cell receptors recognize longer peptides presented by MHC class II, leading to helper T-cell activation and immune coordination[2][8]. The strength and breadth of these responses, particularly to Gag, are associated with more effective HIV immune control[5][7]. However, HIV can evade TCR recognition by mutating epitope sequences or downregulating MHC expression (especially via the Nef protein), contributing to immune escape and persistent infection[1][3][5][7]. Therapeutic and vaccine strategies aim to enhance or redirect TCR responses to these viral epitopes, though the TCR itself is not directly targeted by drugs but represents a key node in immune-based interventions.

Other names

HIV-1 Gag-specific T-cell receptorHIV-1 Pol-specific T-cell receptorHIV-1 Nef-specific T-cell receptorHIV-1 epitope-specific TCR

Antigen-specific TCR engagement with peptide-MHC leads to T-cell activation, cytotoxicity (for CD8+ T cells), or helper function (for CD4+ T cells) depending on MHC class and T-cell subtype[3][4][5][8].